Metrics raised 1
- FY27 net franchisee additions target raised to ~1,700 (from 1,500)
Event Participants
Executives
5
Rahul Guha, Rajdeep Panwar, Ramesh Kinha, Vikram Gupta, Preet Joshi
Analysts
10
Abdulkader Puranwala, Aditya Chheda, Chintan Sheth, Lokesh Manik, Mohammed Patel, Naman Bagrecha, Shubham Harne, Surya Narayan Patra, Yash Singhee, Yogesh
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹240 crores | +24.3% YoY; driven by 26% core pathology growth |
| Standalone Revenue | ₹225.6 crores | +26.1% YoY; franchisee and partnership channels both grew >25% |
| Pathology Test Volume | ~5.5 crore tests | +28% YoY; restated to exclude unbilled calculated parameters |
| Active Franchisees | 11,700 | Highest ever; +900 gross added in Q1; ~4x vs 2,700 in FY21 |
| Franchisee Channel Revenue | +27% YoY | Pay-for-performance structure and doubled field sales team (70) driving additions |
| Partnership Channel Revenue | +26% YoY | Led by insurance/healthtech; API integrations enabling multi-city partner expansion |
| Aarogyam Brand Growth | +21% YoY | Flagship preventive brand; Q1 seasonally softer vs Q4 corporate-benefit peak |
| Jaanch Brand Growth | +36% YoY | ~2% of pathology revenue; curative/chronic lifestyle portfolio scaling |
| Tanzania Business Revenue | ~2x YoY | Strong international momentum; 1 lab operational in Tanzania |
| Radiology Revenue | -4% YoY / +8% QoQ | YoY decline from center consolidation; segment profitability improving |
| Gross Margin | 74.1% | +290 bps YoY; better negotiations, 28% volume growth, operational efficiency |
| EBITDA Margin | 32.2% | EBITDA +34% YoY; expanded from 23% in FY23 (ex-COVID) |
| PAT | ₹51.3 crores | +34% YoY; PAT margin 21.4% |
| EPS | ₹3.23 | vs ₹2.41 prior year; +34% YoY |
| Lab Network | 44 labs (43 India + 1 Tanzania) | 3 new labs opened: Muzaffarpur, Kurnool, Prayagraj |
| Test Menu | 1,375+ tests | Nearly 5x vs FY21; 20+ specialty tests (allergy, genomics) added |
| Turnaround Time | 3.37 hours | Best-in-class for the quarter; improved lab/processes |
| Complaint Rate | 3.1 per million tests | Six Sigma level; proactive patient communication improved |
| NABL Coverage | 97% of samples | 100% own labs NABL-accredited vs ~2% industry average |
| ROCE | 34% (FY26) | Up from 15% in FY23 |
| Cumulative Capex | ₹250+ crores | Since FY21 acquisition; includes specialty central lab investments |
| ESOP Charge | ~₹3.5 crores/quarter | Stabilized; management suggests trailing 4-quarter average for modeling |
Geographic & Segment Commentary
Franchisee Business: Grew 27% YoY with record 11,700 active franchisees. Pay-for-performance structure (~3 years old) is driving volume growth; 900 gross additions in Q1 from a doubled field team (70 vs 35-40 last year) and brand ambassador Madhuri Dixit. Six structured partner meets held across India and Malaysia.
Partnership Business: Grew 26% YoY, led by insurance and healthtech segments. API-based integrations are enabling partners to scale diagnostics offerings across multiple cities, strengthening Thyrocare's B2B positioning.
Preventive Portfolio (Aarogyam & Jaanch): Aarogyam grew 21% YoY (Q1 seasonally weaker as preventive testing peaks in Q4 with corporate benefit expiry). Jaanch, though only 2% of pathology revenue, grew 36% YoY and is emerging as a lifestyle/curative growth pillar.
Specialty Diagnostics: Commercial go-live achieved in Q1 FY27 with Phadia-based allergy platform and 20+ specialized tests including Histopathology, HPLC, NGS, BioFire PCR, Exome Sequencing, and Gut Microbiome. Works through a dedicated specialty commercial team engaging physicians, hospitals, and institutions; centralized lab model at Mumbai/Delhi. Management calls FY27 the "zero year" with no formal targets.
International – Tanzania: Revenue doubled YoY; 1 lab operational. Africa foray aligns with the affordability mission; genomics market globally projected to exceed USD100 billion by 2030.
Radiology: Revenue declined 4% YoY due to center consolidation but grew 8% QoQ with improved profitability. From Q1 FY27, segment reporting includes Nuclear Healthcare Ltd and Pulse Hitech Ltd. Board approved divestment of the nuclear business (~₹140 crores capital, ~₹6 crores annual PAT); process expected to take ~6 months.
Lab Network & Operations: 44 labs total (43 India + 1 Tanzania); 3 new labs opened in Q1 (Muzaffarpur, Kurnool, Prayagraj). TAT at 3.37 hours, complaint rate at 3.1 per million tests, 97% samples processed at NABL-accredited labs, 2,000+ phlebotomists, and 23 doctor meets with ~100 doctors conducted. Bharat Aarogyam Score data shows heart risk doubling by 30s and diabetic risk more than doubling by 40s, supporting early preventive assessment.
Company-Specific & Strategic Commentary
Five-Year Transformation (Since July 2021 Acquisition): Pathology revenue CAGR improved from <10% (FY18-FY20) to 26% in Q1 FY27 (vs 20% in FY26); franchisees grew from 2,700 to 11,700 (4x); labs from 17 to 44; test menu to 1,375+ (nearly 5x); 100+ MD Pathologists added; 100% own labs NABL-accredited vs ~2% industry penetration.
Profitability & Return Transformation: EBITDA margin expanded from 23% (FY23) to 32% (Q1 FY27), with 20%+ EBITDA growth for 8 consecutive quarters; ROCE improved from 15% (FY23) to 34% (FY26), supported by ₹250+ crores cumulative capex.
Specialty Expansion ("Routine to Remarkable"): Entering underpenetrated, premium-priced, fragmented specialty diagnostics by deploying the proven scale/automation/quality/affordability model; NIPT priced at less than half of existing market rates to drive volume-led adoption.
Digital & Technology: Investments across the diagnostic value chain (bookings, logistics, lab operations, reporting) creating a foundation for AI-led preventive healthcare capabilities. Recognized as India's Most Trusted Customer-Focused Diagnostic Brand 2026 and winner of FE Healthcare Awards (Diagnostic Chain of the Year, Pathology Lab Chain of the Year).
Brand & Channel Initiatives: Brand ambassador Madhuri Dixit supporting franchisee acquisition; Thyrocare-branded consumables (not backward integration) to be announced by September 2026.
Parent Company (API Holdings) Deleveraging: Group debt reduced to ₹1,050 crores from ₹1,700-1,800 crores via monetization of non-strategic assets; IPO speculation termed "unfounded" — any corporate action only after API is profitable ex-Thyrocare and debt-free, at least 12 months away.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | Mid-to-high teens (maintained) | Held despite 26% Q1 growth; Q2 FY26 base is high (~₹200 crores vs ~₹180 crores in Q1 FY26); revisit after H1 |
| FY27 Franchisee Additions | ~1,700 net (up from 1,500) | Q1: ~700 net (900 gross, churn expected); Q2: +500; Q3: 0 (seasonally difficult); Q4: +500 |
| Specialty Revenue Mix | 15-20% of portfolio in 3-5 years (ambition) | Peer-benchmarked, not formal guidance; "zero year" for specialty, no internal targets set |
| Radiology Divestment | ~6 months process | Board approval obtained; nuclear business not growing and under-invested; seeking a partner willing to invest; no definitive buyer yet |
| Specialty Capex | Minimal incremental capex in FY27 | Core investments in Mumbai/Delhi central processing labs already complete; expansion capex only if volumes exceed expectations |
| Consumables Announcement | By September 2026 | Thyrocare-branded consumables direction; not backward integration |
| ESOP Charge | ~₹3.5 crores/quarter | Stabilized; use trailing 4-quarter average for estimates |
Risks & Constraints
| Risk | Context |
|---|---|
| Franchisee Churn & Seasonality | 900 gross Q1 additions may not persist — management builds |
| Specialty Execution Risk | Specialty margins could be dilutive "unless we fail completely on the strategy and we don't get volume." NIPT priced at <50% of market requires volume-led returns; no formal targets in the "zero year" add uncertainty |
| Parent Company Leverage & Pledge | API Holdings debt at ₹1,050 crores (down from ₹1,700-1,800); promoter holding 100% pledged per analyst; eBay sold 10% stake; IPO contingent on profitability ex-Thyrocare and debt-free status, at least 12 months away |
| Radiology Capital Drag | ~₹140 crores invested generating only ~₹6 crores annual PAT; nuclear business not growing; divestment timeline of ~6 months with no definitive buyer identified |
| Per-Franchisee Realization Pressure | New Tier 3/4 franchisees enter at lower revenue/sample bases, keeping blended revenue per franchisee flat (~₹500-510); countermeasure is mix shift toward semi-specialized, higher-value tests |
| Test Volume Restatement | Test count now excludes calculated parameters (unbilled, non-machine-processed); historical comparisons require like-for-like adjustment, though management states "hardly any variation" |
Q&A Highlights
Specialty Diagnostics: Ambition, Investments, Doctor Adoption
Question: How significant can genomics/allergy become in 3-4 years, and what investments are planned? (Abdulkader Puranwala, ICICI Securities)
Answer: Too early for formal guidance; peer set runs 15-20% specialty mix, and the ambition is to reach the same in 3-5 years. Investments are largely complete — specialty uses a centralized Mumbai/Delhi lab model, not per-lab capex, so minimal incremental capex is needed next year. (Rahul Guha)
Question: How will you drive prescriptions from doctors in this prescription-driven segment? (Yogesh, Haitong Securities)
Answer: Pathology is ~90% prescription-driven industry-wide; a dedicated scientifically-enabled specialty field team is engaging doctors directly, while the 11,700-franchisee network is used to propagate the specialty menu via software communications. Driving adoption from both ends; "zero year" with no formal targets set. (Rajdeep Panwar)
Specialty Pricing & Margin Impact
Question: Is the specialty entry about volume (preventive playbook) or accessing high margins? (Yogesh, Haitong Securities)
Answer: The mission is affordability — NIPT launched at less than half of existing market prices. The objective is volume capture; margins are comparable if volumes materialize. (Rahul Guha)
Question: Does a 15-20% specialty mix impact overall EBITDA margin? (Mohammed Patel, Edelweiss)
Answer: No — specialty margins should be broadly in line with current EBITDA margin; dilutive only if the strategy fails and volumes don't come. (Rahul Guha)
Franchisee Growth: Target Revision & Drivers
Question: With 900 franchisees added in Q1 vs the 1,500 annual target, will the target be revised? (Shubham Harne, Purnartha)
Answer: Momentum reflects the H2 FY26 sales team expansion (~doubled to 70) and branded store openings; expect 500-700 average net additions per quarter. Revised run-rate ~1,700: 700 in Q1 (900 gross less churn), 500 in Q2, 0 in Q3, 500 in Q4. (Rajdeep Panwar, Rahul Guha)
Question: Volume grew ~20-22% with pricing growth — what worked better than expected versus the mid-to-high teens guidance? (Chintan Sheth, Girik Capital)
Answer: Too early to revise guidance — Q2 FY26 base is strong (~₹200 crores vs ~₹180 crores in Q1 FY26). Franchisee acquisition is being aided by brand ambassador Madhuri Dixit and field team enablement. (Rahul Guha, Rajdeep Panwar)
Franchisee Realization & Test Mix
- Question: Revenue per vial in franchise business crossed ₹250 from a stagnant ~₹240 — is specialty contributing? (Chintan Sheth, Girik Capital)
- Answer: Specialty is <1% of ~5.5 crore tests. The driver is mix shift from thyroid (20% of mix 4 years ago → low single digits today) toward lipids, biochemistry panels, dual/triple/quadruple markers, and PCR-based HIV/HPV tests — higher-realization semi-specialized tests. (Rahul Guha)
Test Volume Restatement
- Question: Why change the definition of tests conducted? (Shubham Harne, Purnartha)
- Answer: Removed calculated parameters that are not billed and don't require machine processing; many such parameters were introduced over the last 6 months, so all quarterly numbers were restated for a fair picture. "Hardly any variation" in the restated data. (Rahul Guha)
Radiology Divestment
Question: What is the timeline for the imaging business divestment? (Abdulkader Puranwala, ICICI Securities)
Answer: The nuclear business has not been growing and was deliberately under-invested due to its ROCE profile; seeking a partner willing to invest and grow it. Process anticipated at ~6 months; no definitive buyer yet. (Rahul Guha)
Question: Is the investment ~₹150 crores with ~₹5-6 crores PAT? (Aditya Chheda, InCred)
Answer: Investment is ~₹140 crores; Q1 PAT was ₹1.72 crores; expect ~₹6 crores for the full year. (Rahul Guha)
Parent Company (API Holdings) & Dividend
- Question: With 100% promoter pledge, dividend payout, and eBay's 10% stake sale, are there API IPO or reverse merger plans? (Sanyam Jain, Valowth Capital)
- Answer: IPO news is "unfounded" speculation. API debt down from ₹1,700-1,800 crores to ₹1,050 crores via non-strategic asset monetization; IPO only when profitable ex-Thyrocare and debt-free — at least 12 months away. No dividend guidance is ever given. (Rahul Guha)
Consumables Update
- Question: Consumables entry — backward integration or branded? (Yash Singhee, Unifi Capital)
- Answer: Direction is Thyrocare-branded consumables, not backward integration; internal strategy; announcement expected by September 2026. (Rahul Guha)
Franchisee Maturation & Growth Algorithm
Question: Should company growth eventually exceed franchisee addition growth as the base matures? (Surya Narayan Patra, PhillipCapital)
Answer: New franchisees contribute only ~5% of revenue in year one, maturing to ~20% by year three; the thesis holds provided franchisee churn stays low. (Rahul Guha)
Question: Revenue per franchisee stuck at ~₹500-510 — will FY25 additions' maturity lift this? (Chintan Sheth, Girik Capital)
Answer: The blended metric stays flat because older franchisees mature while new Tier 3/4 franchisees enter at a lower base; continued focus on higher-value test mix should drive gradual improvement. (Rahul Guha)
Key Takeaway
Thyrocare delivered a strong Q1 FY27 with consolidated revenue of ₹240 crores (+24.3% YoY), standalone revenue of ₹225.6 crores (+26.1%), and 5.5 crore test volumes (+28% YoY), as franchisee (+27%) and partnership (+26%) channels accelerated and EBITDA margin reached 32.2% (EBITDA +34% YoY). PAT grew 34% to ₹51.3 crores, with gross margins up 290 bps to 74.1%. Management maintained mid-to-high teens FY27 revenue guidance citing the high Q2 FY26 base, while revising net franchisee additions to 1,700 (from 1,500) with ~700 net expected in Q1 after churn. Strategic focus centers on specialty diagnostics' commercial go-live (allergy/genomics, 20+ tests, NIPT at <50% of market pricing) targeting 15-20% revenue mix in 3-5 years, and the board-approved radiology divestment (₹140 crores capital, ~₹6 crores annual PAT, ~6-month process). Key watch items include franchisee churn and Q2-Q3 seasonality, specialty volume scaling, and parent API Holdings' deleveraging trajectory (debt at ₹1,050 crores) ahead of any potential IPO.